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Figure 7
CTGTCA'ITAAAGCAACGGTGTI'I‘GTAA GTTCA TCTGTCA TTTTTCA TTTA TTCA CTT

TTATTTTGAGGAGCAGACATGTTAATAATAATTTGGAGCAACTGTAAAGTTATCTAT
'GTGTACAGGTTCGAGCCTCAGGTGCAACCACTAATGCTTGTATTAGATTATGTTGT

CTGCATCATACCCCTAATTGGAGTGTGGCTCTTCCCGAACCCTGCAATGCTGGATG
CTGGATGCTTTATGTATCAGACTGACCTTTTTGTTAAACTATCTAAATACTAAGGAT

GATTTAATAAAAATATAGAATGGTAAACAGAAAAAGATGAGATTATTTTTGGGGCT

ATATGGATTCGCCCGGGCTTTGGGAGGTAAAACGGTATCTACCAGTTGAGACTTTA
CTCCAGAACTTTATCTCGAGAGCTCTGAA TAAAAATGAAA TAGTATTTACCACTCCA
AAATCTTTGA TGGTAAAAA GATGAGA TATAACCTCTTA TAA TTGA TTGAA CCA'CGTT
GATAGAATAAAACTTCTTTACTCCCATTCAGCATAAGAAAAATGAAACCAAACGGA

ATTCTTCTCTTTTTTAGGGGGAAATTCCTTAATTGCTTGTTGAATATAGATTCATGT
CGTTATTCTATTTTTAATAATGATGAAAATCAATATAGTCAAAGTTAATACTTATGT
CATTTGGTTTGCGGACAAGTTATATTGGAACTATATAATACGTCTATTATAGAATAG
TGATTATTTAGAGGATATACATTTTTTTTGGATAAATATTTGATTTATTGGATTAAAA
ATAGAATATACAGGTAAGGTCTAAAACGTGTGTTTGCTTTTACACTAAATAAACTTG
ACCTCGTACAATTCTAAGAAAATA TTTGAAATAAATGAATTATTTTATTGTTAATCA
ATTAAAAAAATCATAGTATAGA TGAGA TGTGTGCA TACTTGGCAATAACTATACTAA
CTAAAACAAGGTATGTGAATAATTGATATTCCTTTTTTAATTATTCTTTTTTCCAGA
GTTTGGTCTTGGATGCAGCAGACACAGTTGCTC'ITCACATAAATTGGGGAATGGC
ATTATTGATAAACAATCAAAAGGCCT'TGACGAAAGCACAAG
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In Burley tobaccos, a positive correlation has been found

ALTERATION OF TOBACCO ALKALOID
CONTENT THROUGH MODIFICATION OF
SPECIFIC CYTOCHROME P450 GENES

betWeen the nornicotine content of the leaf and the amount of

NNN that accumulates in the cured product (Bush et al.
(2001) Rec. Adv. Tob. Sci. 27123-46; Shi et al. (2000)Tob.

Chem. Res. Conf 541Abstract 27). HoWever, keeping norni

CROSS-REFERENCE TO RELATED
APPLICATION

cotine levels at a minimum has been dif?cult because of the
conversion phenomenon that results in a continual introduc

tion of high nornicotine-producing plants Within commer

This application is a continuation-in-part of International

cially groWn Burley populations. Minimizing the number of
Burley plants that accumulate high levels of nornicotine has
traditionally been the responsibility of plant breeders and
seed producers. Though the percentage of converter plants

Application No. PCT/US2005/005665, ?led Feb. 23, 2005,
the content of Which is herein incorporated by reference in its

entirety.
FIELD OF THE INVENTION

that are ultimately groWn in farmers’ ?elds can be reduced

through the roguing of converter plants during the propaga
tion of seed stocks, this process is costly, time-consuming,
and imperfect.

The invention relates to compositions and methods for
reducing the level of nornicotine and its metabolite, N'-ni
trosonornicotine, in a plant that is a member of the genus

Previous studies have shoWn that once a plant has con

Nicoliana, particularly compositions and methods for inhib

ver‘ted, the high nornicotine trait is inherited as a single domi
nant gene (Grif?th et al. (1955) Science 1211343-344; Burk

iting expression or function of a cytochrome P450 polypep
tide involved in the metabolic conversion of nicotine to nor

nicotine.

20

and Jeffrey (1958) Tob. Sci. 21139-141; Mann et al. (1964)
Crop Sci. 41349-353). The nature of this gene, hoWever, is
currently unknoWn. In the most simple of scenarios, the con

BACKGROUND OF THE INVENTION

version locus may represent a nonfunctional nicotine N-dem

The predominant alkaloid found in commercial tobacco
varieties is nicotine, typically accounting for 90-95% of the

25

total alkaloid pool. The remaining alkaloid fraction is com
prised primarily of three additional pyridine alkaloids: nor
nicotine, anabasine, and anatabine. Nornicotine is generated
directly from nicotine through the activity of the enzyme

nicotine N-demethylase (FIG. 1). Nornicotine usually repre

encode a protein that initiates a cascade of events that ulti

mately enables the plant to metabolize nicotine to nomico
tine, Which Would mean that multiple genes may be involved.
30

sents less than 5% of the total pyridine alkaloid pool, but

Regardless of Whether there are one or many genes asso

ciated With the conversion process, it is clear that the gene(s)

encoding polypeptides having nicotine demethylase activity

through a process termed “conversion,” tobacco plants that
initially produce very loW amounts of nornicotine give rise to
progeny that metabolically “convert” a large percentage of
leaf nicotine to nornicotine. In tobacco plants that have

ethylase gene that regains its function in converter plants,
possibly through the mobilization of a mutation-inducing
transposable element. Alternatively, the converter locus may

35

play a pivotal role in this process. Although the inability to
purify active nicotine N-demethylase from crude extracts has
impeded the isolation and identi?cation of this enzyme, there

genetically converted (termed “converters”), the great major

is some evidence that a member of the cytochrome P450

ity of nornicotine production occurs during the senescence

superfamily of monooxygenases may be involved (Hao and
Yeoman (1996) Phylochem. 411477-482; Hao and Yeoman
(1996) Phylochem. 421325-329; Chelvarajan et al. (1993) J.
Agric. Food Chem. 411858-862; Hao and Yeoman (1998) J

and curing of the mature leaf (Wernsman and Matzinger
(1968) Tob. Sci. 121226-228). Burley tobaccos are particu
larly prone to genetic conversion, With rates as high as 20%
per generation observed in some cultivars.

During the curing and processing of the tobacco leaf, a
portion of the nornicotine is metabolized to the compound
N'-nitrosonomicotine (NNN; FIG. 1), a tobacco-speci?c nit
rosamine (TSNA) that has been shoWn to be carcinogenic in
laboratory animals (Hecht and Hoffmann (1990) Cancer Sur
veys 81273-294; Hoffmann et al. (1994) .1. Toxicol. Environ.
Health 4111-52; Hecht (1998) Chem. Res. Toxicol. 111559
603). In ?ue-cured tobaccos, TSNAs Were found to be pre
dominantly formed through the reaction of alkaloids With the
minute amounts of nitrogen oxides present in combustion

40

Plant Physiol. 1521420-426). HoWever, these studies are not
conclusive, as the classic P450 inhibitors carbon monoxide
and tetcylasis have failed to loWer enzyme activity at rates
45

comparable to other reported P450-mediated reactions (Chel
varajan et al. (1993) .1. Agric. Food Chem. 411858-862).
Furthermore, the cytochrome P450s are ubiquitous, trans
membrane proteins that participate in the metabolism of a

Wide range of compounds (revieWed by Schuler (1996) Cril.
Rev Plant Sci. 151235-284; Schuler and Werck-Reichhart
50

(2003)Annu. Rev. Plant Biol. 541629-667). Examples ofbio
chemical reactions mediated by cytochrome P450s include

gases formed by the direct-?red heating systems found in

hydroxylations, demethylations, and epoxidations. In plants,

traditional curing barns (Peele and Gentry (1999) “Formation

the cytochrome P450 gene families are very large. For
example, total genome sequence examination has revealed

of Tobacco-speci?c Nitrosamines in Flue-cured Tobacco,”

CORESTA Meeting, Agro-Phyto Groups, Suzhou, China).
Retro?tting these curing barns With heat-exchangers virtually
eliminated the mixing of combustion gases With the curing air
and dramatically reduced the formation of TSNAs in tobac
cos cured in this manner (Boyette and Ham (2001 ) Rec. Adv.
Tob. Sci. 27117-22). In contrast, in the air-cured Burley tobac
cos, TSNA formation proceeds primarily through reaction of
tobacco alkaloids With nitrite, a process catalyzed by leaf
bome microbes (Bush et al. (2001) Rec. Adv. Tob. Sci. 27123
46). Thus far, attempts to reduce TNSAs through modi?ca

tion of curing conditions While maintaining acceptable
quality standards have not proven to be successful for the
air-cured tobaccos.

55

272 predicted cytochrome P450 genes in Arabidopsis and at
least 455 unique cytochrome P450 genes in rice (see, for

example, Nelson et al. (2004) Plant Physiol. 135(2)1756
772). Even though cytochrome P450 has been implicated as
having a role in the metabolic conversion of nicotine to nor
60

nicotine, identi?cation of key participating members of this
protein family remains a challenge.
Aside from serving as a precursor for NNN, recent studies

suggest that the nornicotine found in tobacco products may
65

have additional undesirable health consequences. Dickerson
and Janda demonstrated that nornicotine causes aberrant pro

tein glycation Within the cell (Dickerson and Janda (2002)
Proc. Natl. Acad. Sci. USA 99115084-15088). Concentrations

US 7,884,263 B2
3

4

of nornicotine-modi?ed proteins Were found to be much

tissues of these plants can be utiliZed to produce tobacco

higher in the plasma of smokers compared to nonsmokers.

products having reduced levels of nomicotine and this

Furthermore, this same study shoWed that nornicotine can

tobacco-speci?c nitrosamine, and thus reduced carcinogenic

covalently modify commonly prescribed steroid drugs such

potential for individuals consuming these products or
exposed to secondary smoke derived from these products.
Also provided are transgenic Nicoliana plants having a

as prednisone. Such modi?cations have the potential of alter

ing both the e?icacy and toxicity of these drugs.
In vieW of the dif?culties associated With conversion and
the undesirable health effects of nomicotine accumulation,
improved methods for reducing the nomicotine content in

nicotine to nomicotine conversion rate of less than about 2%,
Where the plants comprise a heterologous nucleic acid con
struct comprising a promoter capable of functioning in a plant
cell operably linked to a nucleic acid sequence having a ?rst
nucleotide sequence comprising a fragment of betWeen about

tobacco varieties, particularly Burley tobacco, are therefore
desirable. Such methods Would not only help ameliorate the
potential negative health consequences of the nornicotine per

100 nucleotides and about 400 nucleotides of a Nicoliana

se as described above, but should also concomitantly reduce
NNN levels.

nicotine demethylase polynucleotide and a second nucleotide
sequence capable of forming a double- stranded RNA With the
?rst nucleotide sequence, Where the transgenic Nicoliana

SUMMARY OF THE INVENTION

plants are transgenic converter lines of Nicoliana. In some

embodiments, the Nicoliana nicotine demethylase poly
Compositions and methods for reducing the nornicotine
content in plants that are members of the genus Nicoliana are

provided. Compositions include isolated cytochrome P450

20

polynucleotides and polypeptides that are involved in the
metabolic conversion of nicotine to nornicotine in plants,

particularly Nicoliana species. The isolated polynucleotides
comprise the nucleotide sequence set forth in SEQ ID NO: 1,
3, 5, 7, 9, or 1 l, a nucleotide sequence encoding a polypeptide
as set forth in SEQ ID N012, 4, 6, 8, 10, or 12, and fragments
and variants thereof. Isolated polypeptides of the invention
comprise an amino acid sequence set forth in SEQ ID N012,
4, 6, 8, 10, or 12, an amino acid sequence encoded by the
nucleotide sequence set forth in SEQ ID NOzl, 3, 5, 7, 9, or
11, and fragments and variants thereof.
The polynucleotides of the invention ?nd use in suppress
ing expression of a cytochrome P450 that is involved in the

25

30

35

this manner, compositions further include expression cas
settes comprising an inhibitory sequence that is capable of
inhibiting expression or function of a cytochrome P450

genic Nicoliana plant. In some embodiments, the Nicoliana
nicotine demethylase polynucleotide is a tobacco nicotine

demethylase polynucleotide.
40

In some embodiments, the inhibitory sequence comprises the

sequence set forth in SEQ ID NOzl, 3, 5, 7, 9, ll, l3, l4, 15,

also include transformed plants and plant parts that comprise

promoter capable of functioning in a plant cell operably
45

otides and about 400 nucleotides of a Nicoliana nicotine

level of nomicotine, and its related nitrosamine, N'-nitroso
50

The methods of the invention comprise inhibiting the
expression or function of a cytochrome P450 polypeptide of
the present invention. In some embodiments, an expression
cassette comprising an inhibitory sequence that targets
expression or function of a cytochrome P450 polypeptide of
the present invention is introduced into the plant or plant part

demethylase polynucleotide and a second nucleotide
sequence capable of forming a double- stranded RNA With the
?rst nucleotide sequence, Where the transgenic Nicoliana
plants are transgenic converter lines of Nicoliana. In some

embodiments, the Nicoliana nicotine demethylase poly
nucleotide is a tobacco nicotine demethylase polynucleotide.

The present invention also provides transgenic plant cells
55

comprising a nucleic acid molecule having a promoter func
tional in a plant cell and a nucleic acid sequence encoding a
nicotine demethylase having an isoleucine residue at position
274 and a tryptophan residue at position 330.

60

for a nicotine demethylase sequence comprising: obtaining a
nucleic acid sequence that has greater than about 90%
sequence identity With SEQ ID N015 and identifying a codon
sequence encoding for a tryptophan residue at position 330 of

of interest, Wherein expression of the inhibitory sequence
produces a polynucleotide or polypeptide that inhibits
expression or function of a cytochrome P450 polypeptide of
the invention. In one such embodiment, the inhibitory
sequence comprises a sequence set forth in SEQ ID NO: 1, 3,
5, 7, 9, ll, l3, l4, 15, or 16, or a complement or fragment
thereof.
The methods of the invention ?nd use in the production of
Nicoliana plants that have decreased levels of nornicotine and
its metabolite, the nitrosamine N'-nitrosonomicotine, Within
the leaf and stem tissues. When harvested, the leaf and stem

linked to a nucleic acid sequence having a ?rst nucleotide

sequence comprising a fragment of betWeen about 100 nucle

provided are tobacco products, including cheWing tobacco,
snuff, cigarettes, pipe tobacco, and cigars, having a reduced
nomicotine.

The present invention also provides seed obtained from the
transgenic Nicoliana plant having a nicotine to nornicotine
conversion rate of less than about 2%, Where the seed com
prises a heterologous nucleic acid construct comprising a

or 16, or a complement or fragment thereof. Compositions

an expression cassette of the present invention, optionally
stably incorporated into the genome of the plant. Further

otide sequence capable of forming a double-stranded RNA
With the ?rst nucleotide sequence; and regenerating a trans

polypeptide of the invention, Where the inhibitory sequence is
operably linked to a promoter that is functional in a plant cell.

in a plant cell operably linked to a nucleic acid sequence
having a ?rst nucleotide sequence comprising a fragment of
betWeen about 100 nucleotides and about 400 nucleotides of
a tobacco nicotine demethylase polynucleotide and a second
nucleotide sequence capable of forming a double-stranded
RNA With the ?rst nucleotide sequence.
Also provided are methods of reducing the conversion of
nicotine to nornicotine in a Nicoliana plant comprising trans
forming a Nicoliana plant With a recombinant nucleic acid
construct comprising a promoter capable of functioning in a
plant cell operably linked to a nucleic acid sequence having a
?rst nucleotide sequence comprising a fragment of betWeen
about 100 nucleotides and about 400 nucleotides of a Nicoti
ana nicotine demethylase polynucleotide and a second nucle

metabolic conversion of nicotine to nornicotine in a plant,

including the cytochrome P450s of the present invention. In

nucleotide is a tobacco nicotine demethylase polynucleotide.
The present invention also provides a recombinant nucleic
acid construct comprising a promoter capable of functioning

The present invention also provides methods of screening

the encoded polypeptide.
65

Further provided are methods for screening for a nicotine
demethylase having an isoleucine at position 274 or a tryp

tophan at position 330 comprising obtaining a nucleic acid

US 7,884,263 B2
6

5
sequence that has greater than about 90% sequence identity
With SEQ ID N015 and identifying a ?rst codon sequence

FIG. 8A shoWs a diagram of the RNAi constructs used to

silence expression of members of the 3D_CDl2 gene family;
and FIG. 8B shoWs a diagram of the RNAi binary expression
vector, pKYLX7 l /RNAi.

encoding for an isoleucine residue at position 274 or a second

codon sequence encoding a tryptophan residue at position
330 of the encoded polypeptide.

DETAILED DESCRIPTION OF THE INVENTION
BRIEF DESCRIPTION OF THE DRAWINGS

Background and De?nitions
FIG. 1 shoWs the structures of nicotine, nornicotine, and

Before describing the present invention in detail, it is to be

N'-nitrosonornicotine (NNN).

understood that many modi?cations and other embodiments

FIG. 2 shoWs Northern blot analysis of converter and non
converter RNAs using 7D_A06 as a hybridization probe.
Lanes 1 and 2 shoW RNAs isolated from sodium bicarbonate
treated leaves of genotypes DH 98-325-5 (nonconverter) and
DH 98-325-6 (converter), respectively. Lanes 3 and 4 shoW
RNAs isolated from ethephon-treated leaves of genotypes
DH 98-326-3 (nonconverter) and DH 98-326-1 (converter),
respectively. Estimated size of the hybridizing band is indi

of the inventions set forth herein Will come to mind to one

skilled in the art to Which this invention pertains having the

bene?t of the teachings presented in the foregoing descrip
tions and the associated draWings. Therefore, it is to be under
stood that the invention is not to be limited to the speci?c
embodiments disclosed and that modi?cations and other
embodiments are intended to be included Within the scope of

cated in kilobases (kb).
FIG. 3A-3G shoWs a nucleotide sequence alignment of

20

requirements.

members of the 3D_Cl2 gene family. Asterisks denote posi
tions Where sequence identity is conserved among all

Although speci?c terms are employed herein, they are used
in a generic and descriptive sense only and not for purposes of
limitation. Like numbers refer to like elements throughout.

sequences compared. Positions Where differences are found
are indicated With dashes and the corresponding residues are

shaded grey. The nucleotide sequences present in the align

25

ment include 3D_Cl2 (SEQ ID N011), 3D_Cl2-l0 (SEQ ID

one or more element. Throughout the speci?cation the Word
“comprising,” or variations such as “comprises” or “compris
30

Was used to make the RNAi-based construct is underlined.

FIG. 4 shoWs an alignment of predicted amino acid

sequences for full-length members of the 3D_Cl2 family of
P450 genes. The amino acid sequences present in the align
ment include 3D_Cl2 (SEQ ID N012), 3D_Cl2-l0 (SEQ ID

ing,” Will be understood to imply the inclusion of a stated
element, integer or step, or group of elements, integers or
steps, but not the exclusion of any other element, integer or
step, or group of elements, integers or steps.
The present invention is draWn to compositions and meth
ods for inhibiting the expression or function of cytochrome
P450 polypeptides that are involved in the metabolic conver

N014); 3D_Cl2-7 (SEQ ID N016); and 7D_A06 (SEQ ID

sion of nicotine to nornicotine in a plant, particularly plants of
the Nicoliana genus, including tobacco plants of the various
commercial varieties. As used herein, the terms “inhibit,”

N01 8). Asterisks denote positions conserved among all four
sequences. Residues that differ among the members are
shaded in grey.

Further, the article “a” and “an” are used herein to refer to one
or more than one (i.e., to at least one) of the grammatical

object of the article. By Way of example, “an element” means

N013); 3D_Cl2-7 (SEQ ID N015); 7D_A06 (SEQ ID N017);
3D_Cl2-l5 (SEQ ID N019); and 131A_A02 (SEQ ID
N01ll). The 3D_Cl2-l5 and l3lA_A02 entries are partial
length cDNA sequences. The 99 bp region of 3D_Cl2 that

the appended claims. Rather, these embodiments are pro
vided so that this disclosure Will satisfy applicable legal

40

FIG. 5 shoWs a Northern blot analysis of transgenic plants

“inhibition,” and “inhibiting” are de?ned as any method
knoWn in the art or described herein that decreases the expres

possessing the 3D_Cl2/RNAi construct. (A) Hybridization

sion or function of a gene product of interest (i.e., the target

of the 3D_Cl2-7 probe to RNAs isolated from ethephon
treated, cured leaves of transgenic plants displaying loW nor

gene product). “Inhibition” can be in the context of a com

nicotine phenotypes (3D_Cl2/RNAi-l, 3, and 4) and high

45

nomicotine phenotypes (3D_Cl2/RNAi-6, 7, and vector
only control plant 11). Estimated size of hybridizing band is
indicated in kilobases (kb). (B) Ethidium bromide staining of
the portion of the gel used in (A) that contains the 28S ribo
somal RNA to shoW the relative equivalence of RNA loading

expression or function of a target gene product can be in the

context of a comparison betWeen plant cells, organelles,
organs, tissues, or plant parts Within the same plant or

betWeen different plants, and includes comparisons betWeen
50

among the lanes.

includes any relative decrement of function or production of

a gene product of interest, up to and including complete
elimination of function or production of that gene product.

3D_Cl2 gene family. (A) Hybridization of the 3D_Cl2-7
55

dent transgenic lines expressing 3D_Cl2-7, 3D_Cl2, and

product.

(kb). (B) Ethidium bromide staining of the portion of the gel
60

relative equivalence of RNA loading among the lanes.

The term “inhibitory sequence” encompasses any poly
nucleotide or polypeptide sequence capable of inhibiting the
expression or function of a cytochrome P450 polypeptide
involved in the metabolic conversion of nicotine to nomico
tine in a plant, such as full-length polynucleotide or polypep
tide sequences, truncated polynucleotide or polypeptide

FIG. 7 shoWs a genomic sequence of a fragment of the

3D_Cl2-l0 gene (see SEQ ID N01 23) possessing an intron.
Intron sequences are indicated in bold, italicized type. Exon
sequences are shoWn in plain type. The sequences corre

The term “inhibition” encompasses any method or composi

tion that doWn-regulates translation and/or transcription of
the target gene product or functional activity of the target gene

7D_A06 constructs and a vector-only control (control 8).
Estimated size of hybridizing band is indicated in kilobases
used in (A) that contains the 28S ribosomal RNA to shoW the

developmental or temporal stages Within the same plant or

plant part or betWeen plants or plant parts. “Inhibition”

FIG. 6 shoWs a Northern blot analysis of transgenic plants
possessing sense-orientation constructs of members of the
probe to RNAs isolated from nontreated leaves of indepen

parison betWeen tWo plants, for example, a genetically altered
plant versus a Wild-type plant. Alternatively, inhibition of

sponding to the PCR primers used to amplify the fragment

sequences, fragments of polynucleotide or polypeptide
sequences, variants of polynucleotide or polypeptide

from the tobacco genomic DNA are underlined.

sequences, sense-oriented nucleotide sequences, antisense
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oriented nucleotide sequences, the complement of a sense- or

genetic modi?cation at the genomic locus encoding a cyto

antisense-oriented nucleotide sequence, inverted regions of
nucleotide sequences, hairpins of nucleotide sequences,
double-stranded nucleotide sequences, single-stranded
nucleotide sequences, combinations thereof, and the like. The
term “polynucleotide sequence” includes sequences of RNA,
DNA, chemically modi?ed nucleic acids, nucleic acid ana
logs, combinations thereof, and the like.
Inhibitory sequences are designated herein by the name of

chrome P450 polypeptide of the invention can shoW reduced
or eliminated expression or activity of that cytochrome P450

polypeptide.
The term “introducing” is intended to mean presenting to
the plant the polynucleotide or polypeptide in such a manner
that the sequence gains access to the interior of a cell of the

plant.
The term “operably linked” is intended to mean a func
tional linkage betWeen tWo or more elements. For example,

the target gene product. Thus, a “cytochrome P450 inhibitory
sequence” refers to an inhibitory sequence that is capable of

an operable linkage betWeen a polynucleotide of interest and
a regulatory sequence (i.e., a promoter) is a functional link
that alloWs for expression of the polynucleotide of interest.
Operably linked elements may be contiguous or non-contigu
ous. When used to refer to the joining of tWo protein coding

inhibiting the expression of a cytochrome P450 polypeptide
that is involved in the metabolic conversion of nicotine to

nomicotine in a plant, for example, at the level of transcrip
tion and/or translation, or Which is capable of inhibiting the
function of such a cytochrome P450 polypeptide. When the
phrase “capable of inhibiting” is used in the context of a
polynucleotide inhibitory sequence, it is intended to mean
that the inhibitory sequence itself exerts the inhibitory effect;
or, Where the inhibitory sequence encodes an inhibitory

regions, by operably linked is intended that the coding regions
are in the same reading frame.

The term “heterologous” according to the present inven
tion When used in reference to a sequence is intended to mean
20

nucleotide molecule (for example, hairpin RNA, miRNA, or

a sequence that originates from a foreign species, or, if from
the same species, is substantially modi?ed from its native

double-stranded RNA polynucleotides), or encodes an inhibi

form in composition and/or genomic locus by deliberate

tory polypeptide (i.e., a polypeptide that inhibits expression

human intervention. The term also is applicable to nucleic
acid constructs, also referred to herein as “polynucleotide

or function of the target gene product), folloWing its transcrip
tion (for example, in the case of an inhibitory sequence encod

25

ing a hairpin RNA, miRNA, or double-stranded RNA poly
nucleotide) or its transcription and translation (in the case of
an inhibitory sequence encoding an inhibitory polypeptide),
the transcribed or translated product, respectively, exerts the

inhibitory effect on the target gene product (i.e., inhibits
expression or function of the target gene product).
By “host cell” is meant a cell that comprises a heterologous
nucleic acid sequence of the invention. Though the nucleic
acid sequences of the invention, and fragments and variants
thereof, can be introduced into any cell of interest, of particu

30

not limited to, recombinant nucleotide constructs that have

via transformation methods or subsequent breeding of a

transgenic plant With another plant of interest.
35

ana plant species, for example, the tobacco plant species and
varieties described herein beloW.
The use of the term “polynucleotide” is not intended to
40

For example, a promoter operably linked to a heterologous
polynucleotide is from a species different from the species
from Which the polynucleotide Was derived, or, if from the
same/analogous species, one or both are substantially modi
?ed from their original form and/or genomic locus, or the
promoter is not the native promoter for the operably linked
polynucleotide. Furthermore, as used herein a chimeric gene
comprises a coding sequence operably linked to a transcrip

tion initiation region that is heterologous to the coding

deoxyribonucleotides and ribonucleotides include both natu

rally occurring molecules and synthetic analogues. The poly

struct that originates from a foreign species, or, if from the
same species, is substantially modi?ed from its native form in
composition and/ or genomic locus by deliberate human inter
vention. Heterologous nucleic acid constructs include, but are

been introduced into a plant or plant part thereof, for example,

lar interest are plant cells, more particularly cells of a Nicoti

limit the present invention to polynucleotides comprising
DNA. Those of ordinary skill in the art Will recogniZe that
polynucleotides can comprise ribonucleotides and combina
tions of ribonucleotides and deoxyribonucleotides. Such

constructs” or “nucleotide constructs.” In this manner, a “het
erologous” nucleic acid construct is intended to mean a con

45

nucleotides of the invention also encompass all forms of

sequence.
The term “expression” as used herein refers to the biosyn

thesis of a gene product, including the transcription and/or
translation of said gene product. For example, for the pur
poses of the present invention, an expression cassette, as
described elseWhere herein, capable of expressing a poly

sequences including, but not limited to, single-stranded

forms, double-stranded forms, hairpins, stem-and-loop struc
tures, and the like.

The term “variant” as used herein is intended to mean a 50 nucleotide that inhibits the expression of at least one cyto

substantially similar sequence, and the term “native” poly

55

chrome P450 polypeptide of the invention is an expression
cassette capable of producing an RNA molecule that inhibits
the transcription and/or translation of at least one cytochrome
P450 polypeptide. The “expression” or “production” of a
protein or polypeptide from a DNA molecule refers to the
transcription and translation of the coding sequence to pro
duce the protein or polypeptide, While the “expression” or
“production” of a protein or polypeptide from an RNA mol
ecule refers to the translation of the RNA coding sequence to

60

produce the protein or polypeptide.

stems, branches, fruit, roots, root tips, and the like. Progeny,

Cytochrome 450 Polynucleotides and Polypeptides, andVari

variants, and mutants of regenerated plants are also included
Within the scope of the invention, provided that these com
prise the introduced nucleic acid sequences of the invention.
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ants and Fragments Thereof
Compositions of the present invention include isolated
cytochrome P450 polynucleotides and polypeptides that are
involved in the metabolic conversion of nicotine to nomico
tine in plants, including commercial varieties of tobacco

nucleotide or polypeptide is intended to mean a naturally

occurring nucleotide sequence or amino acid sequence,

respectively. By “fragment” is intended a portion of a poly
nucleotide or a portion of an amino acid sequence and hence

protein encoded thereby.
As used herein, the term “plant part” includes plant cells,
plant protoplasts, plant cell tissue cultures from Which a

Whole plant can be regenerated, plant calli, plant clumps, and
plant cells that are intact in plants or parts of plants such as

embryos, pollen, anthers, ovules, seeds, leaves, ?owers,

By “phenotypic change” is intended a measurable change
in one or more cell functions. For example, plants having a

US 7,884,263 B2
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plants. In particular, compositions of the invention include
isolated polypeptides comprising the amino acid sequences
as shoWn in SEQ ID NOS12, 4, 6, 8, 10, and 12, and isolated

full-length 517 residue polypeptide set forth in SEQ ID N016.
The fourth member of the novel cytochrome P450 family,
designated 7D_A06, encodes an mRNA transcript corre

polynucleotides comprising the nucleotide sequences as

sponding to nt 1-1554 of the cDNA sequence set forth in SEQ

shoWn in SEQ ID NOS11, 3, 5, 7, 9, and 11. The polynucle

ID N017, Which codes for the full-length 518-residue
polypeptide set forth in SEQ ID N018.
TWo partial-length P450 gene sequences sharing high
sequence identity to the full-length members of the 3D_C12
cytochrome P450 gene family Were also isolated from these

otides of the invention ?nd use in inhibiting expression of
these cytochrome P450 polypeptides or variants thereof that
are involved in the metabolic conversion of nicotine to nor

nicotine in plants, particularly tobacco plants.

Burley tobacco lines. The ?rst of these, designated 3D_C12

In this manner, the invention further provides expression
cassettes comprising all or a portion of the polynucleotide
sequence set forth in SEQ ID N011, 3, 5, 7, 9, or 11, a
complement or fragment thereof, or a sequence having sub
stantial sequence identity to SEQ ID N011, 3, 5, 7, 9, or 11, or
a complement or fragment thereof, operably linked to a pro

15, encodes an mRNA transcript corresponding to the cDNA
sequence set forth in SEQ ID N019, Which encodes the par
tial-length polypeptide set forth in SEQ ID N0110. The sec

ond partial-length P450 gene sequence, designated
131A_A02, encodes an mRNA transcript corresponding to

moter that is functional in a plant cell for use in expressing an

the cDNA sequence set forth in SEQ ID N0111, Which

inhibitory RNA transcript that interferes With expression (i.e.,
transcription and/or translation) of cytochrome P450

N01 12.

polypeptides described herein. In some embodiments, the
expression cassettes comprise the nucleotide sequence as
shoWn in SEQ ID N0113, 14, 15, or 16, a complement or
fragment thereof, or a sequence having substantial sequence
identity to SEQ ID N0113, 14, 15, or 16, or a complement or
fragment thereof. Introduction of these expression cassettes
into a Nicoliana plant of interest, particularly a tobacco plant
of varieties commonly knoWn as ?ue or bright varieties, Bur

encodes the partial-length polypeptide set forth in SEQ ID
In one aspect, the cytochrome P450 genes of the present
20

the present invention have nicotine demethylase activity.
An alignment of the members of the 3D_C12 cytochrome
P450 gene family is shoWn in FIG. 3A-3G. The predicted
25

amino acid sequences for the four full-length clones are

aligned in FIG. 4. These sequences share high sequence iden
tity With each other (at least 90% at both the nucleotide and
amino acid level (see Tables 2 and 3, Example 4 herein

ley varieties, dark varieties, and oriental/Turkish varieties,
results in the production of tobacco plants having reduced
amounts of nomicotine and the nitrosamine, N'-nitrosonorni
cotine (NNN). Leaf and stem material from these transgenic
plants can be used to produce a variety of tobacco products
having reduced levels of nornicotine, and a concomitant
reduction in this carcinogenic nitrosamine metabolite.
The cytochrome P450 polynucleotides and encoded
polypeptides of the present invention represent a novel cyto

invention are involved in the conversion of nicotine to norni
cotine in a plant. In one aspect, the cytochrome P450 genes of

beloW).
30

The invention encompasses isolated or substantially puri
?ed polynucleotide or protein compositions. An “isolated” or

“puri?ed” polynucleotide or protein, or biologically active
35

portion thereof, is substantially or essentially free from com
ponents that normally accompany or interact With the poly
nucleotide or protein as found in its naturally occurring envi

chrome P450 gene family, designated the 3D_C12 cyto

ronment. Thus, an isolated or puri?ed polynucleotide or

chrome 450 gene family, that is neWly identi?ed as having a
role in the metabolic conversion of nicotine to nomicotine in

protein is substantially free of other cellular material, or cul
ture medium When produced by recombinant techniques, or

tobacco plants. Suppression of the expression of their
encoded gene products in transgenic tobacco plants results in

substantially free of chemical precursors or other chemicals
40

a signi?cant reduction in the accumulation of nomicotine in

the leaves of these transgenic plants. While not being bound
by theory, the metabolic role of these polypeptides may be a
direct one, i.e., directly catalyZing the N-demethylation reac
tion, or an indirect one, i.e., in the form of production of a

sequences located at the 5' and 3' ends of the polynucleotide)
45

product that leads to the up-regulation of the nicotine dem
any means by Which expression and/or function of the

polypeptides encoded by members of this cytochrome P450
50

plant Will be effective in reducing nomicotine levels, and
levels of its carcinogenic metabolite, NNN, Within leaves and
stems of these plants.
The cytochrome P450 genes of the invention Were isolated
from tobacco lines of a Burley variety. The ?rst of these
cytochrome P450 genes, designated 3D_C12, encodes an
mRNA transcript corresponding to nucleotides (nt) 1-1551 of
the cDNA sequence set forth in SEQ ID N011, Which codes
for the full-length 517-residue polypeptide set forth in SEQ
ID N012. The second member of this novel cytochrome P450

that naturally ?ank the polynucleotide in genomic DNA of the
cell from Which the polynucleotide is derived. A protein that
is substantially free of cellular material includes preparations
of protein having less than about 30%, 20%, 10%, 5%, or 1%

(by dry Weight) of contaminating protein. When the protein of
the invention or biologically active portion thereof is recom
55

binantly produced, optimally culture medium represents less
than about 30%, 20%, 10%, 5%, or 1% (by dry Weight) of
chemical precursors or non-protein-of-interest chemicals.

Fragments of the disclosed cytochrome P450 polynucle
otides and polypeptides encoded thereby are also encom
60

family, designated 3D_C12-10, encodes an mRNA transcript

passed by the present invention. Fragments of a polynucle
otide may encode protein fragments that retain the biological
activity of the native protein and hence are involved in the
metabolic conversion of nicotine to nomicotine in a plant.
Alternatively, fragments of a polynucleotide that are useful as

corresponding to nt 1-1551 of the cDNA sequence set forth in

SEQ ID N013, Which codes for the full-length 517-residue
polypeptide set forth in SEQ ID N014. The third of these
cytochrome P450 genes, designated 3D_C12-7, encodes an
mRNA transcript corresponding to nt 1-1551 of the cDNA
sequence set forth in SEQ ID N015, Which codes for the

in the genomic DNA of the organism from Which the poly
nucleotide is derived. For example, in various embodiments,
the isolated polynucleotide can contain less than about 5 kb,
4 kb, 3 kb, 2 kb, lkb, 0.5 kb, or 0.1 kb ofnucleotide sequence

ethylase activity of the leaf. Regardless of the mechanism,
gene family are targeted for inhibition Within a Nicoliana

When chemically synthesiZed. 0ptimally, an “isolated” poly
nucleotide is free of sequences (optimally protein encoding
sequences) that naturally ?ank the polynucleotide (i.e.,
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hybridization probes or PCR primers using methods
described beloW generally do not encode fragment proteins

retaining biological activity. Furthermore, fragments of the
disclosed nucleotide sequences include those that can be

